Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigneron, Nathalie, van Baren, Nicolas, Van den Eynde, Benoît J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485782/
https://www.ncbi.nlm.nih.gov/pubmed/26155395
http://dx.doi.org/10.1080/2162402X.2014.1003012
_version_ 1782378815964577792
author Vigneron, Nathalie
van Baren, Nicolas
Van den Eynde, Benoît J
author_facet Vigneron, Nathalie
van Baren, Nicolas
Van den Eynde, Benoît J
author_sort Vigneron, Nathalie
collection PubMed
description Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO1 was also expressed in 56% of tumors, either by tumoral, stromal, or endothelial cells. These results and reagent will guide the clinical development of IDO1 inhibitors for cancer therapy.
format Online
Article
Text
id pubmed-4485782
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-44857822016-02-03 Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance Vigneron, Nathalie van Baren, Nicolas Van den Eynde, Benoît J Oncoimmunology Author's View Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO1 was also expressed in 56% of tumors, either by tumoral, stromal, or endothelial cells. These results and reagent will guide the clinical development of IDO1 inhibitors for cancer therapy. Taylor & Francis 2015-02-03 /pmc/articles/PMC4485782/ /pubmed/26155395 http://dx.doi.org/10.1080/2162402X.2014.1003012 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Vigneron, Nathalie
van Baren, Nicolas
Van den Eynde, Benoît J
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title_full Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title_fullStr Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title_full_unstemmed Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title_short Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
title_sort expression profile of the human ido1 protein, a cancer drug target involved in tumoral immune resistance
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485782/
https://www.ncbi.nlm.nih.gov/pubmed/26155395
http://dx.doi.org/10.1080/2162402X.2014.1003012
work_keys_str_mv AT vigneronnathalie expressionprofileofthehumanido1proteinacancerdrugtargetinvolvedintumoralimmuneresistance
AT vanbarennicolas expressionprofileofthehumanido1proteinacancerdrugtargetinvolvedintumoralimmuneresistance
AT vandeneyndebenoitj expressionprofileofthehumanido1proteinacancerdrugtargetinvolvedintumoralimmuneresistance

Ejemplares similares